Low-dose buprenorphine to improve social drive in schizophrenia
Treatments studied
Part of Mental health clinical trials.
This study tests whether low-dose buprenorphine can improve social motivation in people with schizophrenia. It compares social motivation changes while keeping participants stable on treatment and avoiding certain medicines and substances.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have a diagnosis of schizophrenia (by DSM-5 criteria)
- Your social motivation score is lower than average on a social network questionnaire
- Your illness and medications are stable for the last 6 months (no hospital stays, no med changes, and symptoms not too severe)
- You do not use opioid medicines, and you do not have opioid use disorder history
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether offering buprenorphine (a medication that reduces cravings and withdrawal) directly at syringe service programs (places where people get clean needles) can help people with opioid addiction stay safe and reduce overdose risk. If you use opioids and visit a syringe service program, this may be an option to explore.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This study compares different treatments for opioid dependence, specifically looking at a new way of giving buprenorphine (a medicine that reduces cravings) versus standard treatment. If you have opioid dependence, this trial might help find a more convenient and effective treatment option.
This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.
This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.
This study tests a new way to receive buprenorphine—a once-a-month injection—from a mobile clinic that comes to you. It aims to make treatment more convenient and acceptable for people with opioid use disorder.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.